← Becton Dickinson and overview

Becton Dickinson and vs Illumina: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Becton Dickinson and Company (BDX)

Q3 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

September 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Latest
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Illumina Inc (ILMN)

Q3 2026
▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

  • Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.

    This point explains the fundamental business strength that drove the stock higher.

  • S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.

    This point captures the market and partnership catalysts that amplified the stock's rise.

  • Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.

    This point highlights the main competitive threat that could pressure future growth.

August 2026
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 2026
▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.